UNSPSC 51391811: Methoxyphenamine hydrochloride

This classification denotes a beta-adrenergic agonist with the molecular formula C11H17NO.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 52V8BVV7FX, chemically known as 2-methoxy-n,alpha-dimethylphenethylamin but more generally known as methoxyphenamine hydrochloride, which bears US NIH Compound Identifier 4117. European Medicines Agency schedules Methoxyphenamine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03229MIG.

Most nations, for tariff and trade purposes, schedule methoxyphenamine hydrochloride under HS 29222900 and SITC 51462. As of Q4 2014, METHOXYPHENAMINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Methoxyphenamine hydrochloride bears US NLM identifiers UMLS ID C0770481 and NCI Concept Code C83959. SMILES: CC(CC1CCCCC1OC)NC.CL.

UNSPSC 51391811 Methoxyphenamine hydrochloride is a Commodity code for a pharmaceutical active ingredient, but state and local procurement records show little relevant recent activity under this code. The single recent opportunity in the dataset—Seminole County, Florida's solicitation for naloxone and drug deactivation systems—involves finished pharmaceutical products and medical devices for emergency response and public health, not the chemical compound itself.

Seminole County issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding with a July 26, 2023 response deadline. The procurement is designed to support community health initiatives with quarterly deliveries to the Seminole County Community Health Building; vendors must include all shipping and delivery costs in their bids and comply with drug-free workplace certification, E-Verify, and federal compliance requirements including the Clean Air Act and Federal Water Pollution Control Act. The contract carries a two-year initial term with a one-year renewal option and a three-month probationary period. This code does not appear to reflect the actual pharmaceutical sourcing practices of state and local health agencies, which typically procure finished medications and devices through group purchasing organizations, state health department contracts, or federal cooperative purchasing vehicles rather than individual chemical compounds at the UNSPSC commodity level. The mismatch suggests this code sees minimal direct state and local procurement activity.